title: Steroidogenic effects of lipoproteins and 25-hydroxycholesterol on luteal and ovarian cells: a comparison of two pseudopregnant rat models.
abstract: Steroidogenesis was compared between luteal cells from immature pseudopregnant (PSP) rats induced by either 5 IU pregnant mare serum gonadotropin (PMSG) alone or 50 IU PMSG combined with 25 IU human chorionic gonadotropin (hCG). It was also determined whether differences in steroidogenesis existed when the entire ovary (ovarian cells) or just luteal cells from Day 4 PSP rats were exposed in vitro to lipoproteins or 25-hydroxycholesterol (25-OH chol). In the absence of luteinizing hormone (LH), basal steroid accumulation, especially progesterone (P4) was around fourfold greater in luteal cells from rats treated with PMSG alone than from rats receiving PMSG-hCG. However, serum P4 and LH were about fivefold greater in the latter group. It is therefore likely that net cellular cholesterol uptake per luteal cell is lower in the PMSG-hCG treated rats, but this is offset by a much greater mass and number of corpora lutea. Lipoproteins (HDL and LDL) and 25-OH chol stimulated in vitro luteal steroidogenesis from rats treated with PMSG alone or PMSG-hCG, and their responses were virtually identical. Therefore, luteal steroidogenesis in the rat always depends on exogenous cholesterol even though treatment in the preovulatory period with PMS or PMSG-hCG and serum LH and follicle-stimulating hormone (FSH) levels on Day 4 PSP are very different. When ovarian cells from PMSG-hCG treated rats were incubated with LH plus HDL or 25-OHP, the production of 20 alpha-DHP was considerably greater than luteal cell production which may be due to a contribution from nonluteal cells. Indeed, about 30% of the cells in the PMSG-hCG group represent nonluteal components as estimated by weight and deoxyribonucleic acid content.
mesh_terms: D004092:20-alpha-Dihydroprogesterone / Q000096:biosynthesis / Q000097:blood; D000818:Animals; D006063:Chorionic Gonadotropin / Q000494:pharmacology; D005260:Female; D006064:Gonadotropins, Equine / Q000494:pharmacology; D006065:Gonadotropins, Pituitary / Q000096:biosynthesis / Q000097:blood; D006888:Hydroxycholesterols / Q000494:pharmacology*; D066298:In Vitro Techniques; D008074:Lipoproteins / Q000494:pharmacology*; D008075:Lipoproteins, HDL / Q000494:pharmacology; D008077:Lipoproteins, LDL / Q000494:pharmacology; D008184:Luteal Cells / Q000187:drug effects / Q000378:metabolism; D010053:Ovary / Q000187:drug effects / Q000378:metabolism*; D011374:Progesterone / Q000096:biosynthesis / Q000097:blood; D011555:Pseudopregnancy / Q000378:metabolism*; D011863:Radioimmunoassay; D051381:Rats; D013256:Steroids / Q000096:biosynthesis*
chemical_list: D006063:Chorionic Gonadotropin; D006064:Gonadotropins, Equine; D006065:Gonadotropins, Pituitary; D006888:Hydroxycholesterols; D008074:Lipoproteins; D008075:Lipoproteins, HDL; D008077:Lipoproteins, LDL; D013256:Steroids; D004092:20-alpha-Dihydroprogesterone; D011374:Progesterone; C007997:25-hydroxycholesterol